COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04410328

Amit Singla, MD

as3321@njms.rutgers.edu

2020-06-01

Completed

RCT

Randomized

Parallel

Open label

single-center

Treatment

inclusion criteria: age ≥18 years. hospitalization. sars-cov-2 viral nucleic acid positive within 3 days. lab test result pending plus a high clinical suspicion for sars-cov-2 (fever and cough for ≤ 7 days, bilateral pulmonary infiltrates on imaging or new hypoxemia with spo2 ≤94% on room air or no alternative explanation for respiratory symptoms). willing and able to provide consent or by authorized proxy.

pregnancy. g-6pd deficiency. use of antiplatelet agents including inhibitor of p2y12 adp platelet receptors, phosphodiesterase inhibitors, and glycoprotein iib/iiia inhibitors. on therapeutic anticoagulation with coumadin, heparin and direct oral anticoagulants. vasodilatory shock. patient with known ongoing angina, recent myocardial infarction and sub-valvular aortic stenosis. active gastric or duodenal ulcer or any bleeding disorder. hemoglobin <9 mg/dl, platelet count of <30,000 /mm3. acute respiratory infection for >10 days. known allergy/hypersensitivity to dipyridamole and/or aspirin. severe hepatic or renal insufficiency. uncontrolled hypertension defined as systolic > 180 mm hg or diastolic > 100 mm hg. patients with known allergy to nsaids

2

Rutgers, The State University of New Jersey

19

100

United States

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

99

Covid (Coronavirus Disease-19) Ordinal Scale

None

Phase 3

[{"arm_notes": "", "treatment_id": 1487, "treatment_name": "Aspirin+dipyridamole", "treatment_type": "Coagulation modifiers", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]